A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Tivozanib (Primary) ; Nivolumab
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms TiNivo
- Sponsors AVEO Oncology
- 16 Oct 2017 According to an AVEO Oncology media release, phase 1 portion of the trial enrolled six patients and enrollment in the Phase 2 portion in ongoing.
- 16 Oct 2017 According to an AVEO Oncology media release, data from the phase 1 part of this study will be presented at the 16th International Kidney Cancer Symposium.
- 05 Oct 2017 According to AVEO Oncology media release, results from phase I portion of this study have been submitted for the presentation at the medical meeting taking place in the fourth quarter of 2017.